Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma
Background: B3 type thymoma is defined as a well-differentiated thymic carcinoma and is similar to a thymic carcinoma. However, the differences between them are not well defined. In addition, the data to compare the efficacy and safety of platinum-based chemotherapy as first-line therapy between B3...
Main Authors: | Yue Hao, Jinfei Si, Jianan Jin, Jingwen Wei, Jing Xiang, Chunwei Xu, Zhengbo Song |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/29/12/743 |
Similar Items
-
Chemotherapy in the treatment of thymic tumors
by: Marcello Tiseo, et al.
Published: (2011-12-01) -
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐line chemotherapy regimens
by: Wei‐Li Ma, et al.
Published: (2022-09-01) -
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
by: Yang Wang, et al.
Published: (2019-01-01) -
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
by: Yelan Guan, et al.
Published: (2023-08-01) -
Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999-2019
by: Tiemo Sven Gerber, et al.
Published: (2024-01-01)